AIMTo examine the expression of prostate cancer antigen-1 (PCA-1) in prostate cancer (PCa) and to validate it as a potential marker for diagnosis of PCa.

METHODSIn situ hybridization analysis of PCA-1 mRNA expression was performed on 40 benign prostate hyperplasia (BPH), 16 high-grade prostatic intraepithelial neoplasm (HG-PIN), 74 PCa and 34 other malignant carcinoma specimens. The level of PCA-1 expression was semiquantitatively scored by assessing both the percentage and intensity of PCA-1 positive staining cells in the specimens. We then compared the PCA-1 expression between BPH, HG-PIN and PCa and evaluated the correlation of PCA-1 expression level with clinical parameters of PCa.

RESULTSPCA-1 mRNA was expressed in the majority of both PCa and HG-PIN specimens but not in BPH and other malignant carcinoma. The expression level of PCA-1 increased along with a high Gleason score (P < 0.05), and was unrelated to other clinical parameters of PCa (all P > 0.05).

CONCLUSIONThe data suggest that PCA-1 might be a novel diagnostic marker for PCa, and that increased PCA-1 expression might denote more aggressive variants of PCa.

Aged ; Antigens, Neoplasm ; metabolism ; Biomarkers, Tumor ; metabolism ; Biopsy ; DNA, Complementary ; metabolism ; Diagnosis, Differential ; Humans ; Male ; Middle Aged ; Prognosis ; Prostate ; metabolism ; pathology ; Prostatic Hyperplasia ; diagnosis ; metabolism ; pathology ; Prostatic Intraepithelial Neoplasia ; diagnosis ; metabolism ; pathology ; Prostatic Neoplasms ; diagnosis ; metabolism ; pathology ; RNA, Messenger ; metabolism

OBJECTIVETo study the expression of the Trp-p8 protein in the prostate tissue of the PSA "grey zone" with different PSA density of the transition zone (PSADTZ) and explore the value of determining Trp-p8 expression and PSADTZ in the early diagnosis of prostate cancer (PCa).

METHODSThis study involved 30 cases of benign prostatic hyperplasia (BPH) and another 30 cases of PCa with different PSADTZ values. Using a data imaging and analysis system, we determined the expression levels of Trp-p8 in BPH and PCa tissues and analyzed their correlation with PSADTZ.

RESULTSThe expression of Trp-p8 was weak or negative in the BPH but strong in the PCa tissue and even stronger in the PCa tissue with high PSADTZ (F = 34. 05, P < 0.05).

CONCLUSIONThe Trp-p8 protein is expressed differently in BPH and PCa tissues of the PSA " grey zone" and its expression is positively correlated with PSADTZ. Determination of the Trp-p8 expression and PSADTZ contributes to the early diagnosis of prostate cancer.

Biomarkers, Tumor ; metabolism ; Early Detection of Cancer ; methods ; Humans ; Male ; Prostate ; metabolism ; Prostate-Specific Antigen ; metabolism ; Prostatic Hyperplasia ; diagnosis ; metabolism ; Prostatic Neoplasms ; diagnosis ; metabolism ; TRPM Cation Channels ; metabolism

The over expression of fatty acid synthase (FAS), a key enzyme in biosynthesis of fatty acid, can enhance enzyme activity and result in the malignant behavior, special material metabolism and energy metabolism of tumors. The expression of FAS is significantly higher in prostate cancer than in normal prostate tissues, which shows that FAS can be used as a marker in the early diagnosis of prostate cancer. The abnormally increased expression of FAS in prostate cancer may offer a new target for the drug treatment of the disease.
Biomarkers, Tumor ; metabolism ; Early Diagnosis ; Fatty Acid Synthases ; metabolism ; Humans ; Male ; Prostatic Neoplasms ; diagnosis ; enzymology

BACKGROUNDThe specificity for early interventions of prostate-specific antigen (PSA) in prostate cancer (PCa) is not satisfactory. It is likely that prostate cancer antigen 3 (PCA3) can be used to predict biopsy outcomes more accurately than PSA for the early detection of PCa. We systematically reviewed literatures and subsequently performed a meta-analysis.

METHODSA bibliographic search in the database of Embase, Medline, Web of Science, NCBI, PubMed, CNKI, and those of health technology assessment agencies published before April 2013 was conducted. The key words used were "prostatic neoplasms", "prostate", "'prostate', 'carcinoma' or 'cancer' or 'tumor', or 'PCa,'" and free terms of "upm3", "pca3", "dd3", "aptimapca 3", and "prostate cancer antigen 3". All patients were adults. The intervention was detecting PCA3 in urine samples for PCa diagnosis. We checked the quality based on the QUADAS criteria, collected data, and developed a meta-analysis to synthesize results. Twenty-four studies of diagnostic tests with moderate to high quality were selected.

RESULTSThe sensitivity was between 46.9% and 82.3%; specificity was from 55% to 92%; positive predictive value had a range of 39.0%-86.0%; and the negative predictive value was 61.0%-89.7%. The meta-analysis has heterogeneity between studies. The global sensitivity value was 0.82 (95% CI 0.72-0.90); specificity was 0.962 (95% CI 0.73-0.99); positive likelihood ratio was 2.39 (95% CI 2.10-2.71); negative likelihood ratio was 0.51 (95% CI 0.46-0.86); diagnostic odds ratio was 4.89 (95% CI 3.94-6.06); and AUC in SROC curve was 0.744 1.

CONCLUSIONPCA3 can be used for early diagnosis of PCa and to avoid unnecessary biopsies.

Antigens, Neoplasm ; metabolism ; Biomarkers, Tumor ; metabolism ; Biopsy ; Humans ; Male ; Prostatic Neoplasms ; diagnosis ; metabolism

Prostate specific antigen (PSA) has a wide clinical use for the early detection of prostatic carcinoma (PCa); however, it has never been a perfect marker due to its low specificity and low positive predictive value which ranges between 4 ng/ml and 10 ng/ml. The discovery of different PSA molecular forms in serum in the early 1990s brought insight into searching for more specific markers. Since then free PSA (fPSA) has been used routinely to increase the specificity for PCa and to reduce unnecessary biopsies. More recently, promising data is emerging regarding one proenzyme molecular form of free PSA, proPSA, and a few truncated proPSA isoforms. The purpose of this article is to review the recent studies on clinical utility of proPSA, especially [−2]pPSA, an isoform of proPSA, and parameters involving [−2]pPSA as well as other PSA derivatives in early detection of PCa.
Biomarkers, Tumor ; metabolism ; Humans ; Male ; Prostate-Specific Antigen ; metabolism ; Prostatic Neoplasms ; diagnosis ; metabolism

Adenocarcinoma ; diagnosis ; metabolism ; pathology ; Carcinoma, Signet Ring Cell ; diagnosis ; metabolism ; pathology ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Neoplasm, Residual ; metabolism ; Prostatic Hyperplasia ; metabolism ; Prostatic Intraepithelial Neoplasia ; metabolism ; Prostatic Neoplasms ; diagnosis ; metabolism ; pathology ; Racemases and Epimerases ; metabolism ; Sensitivity and Specificity

Adenocarcinoma ; metabolism ; pathology ; Atrophy ; Biomarkers ; metabolism ; Diagnosis, Differential ; Humans ; Male ; Prostate ; pathology ; Prostatic Diseases ; metabolism ; pathology ; Prostatic Hyperplasia ; metabolism ; pathology ; Prostatic Neoplasms ; metabolism ; pathology ; Prostatitis ; metabolism ; pathology ; Xanthomatosis ; metabolism ; pathology

Hypoxia-inducible factor 1 (HIF-1) has a close relation with prostate cancer. It is involved not only in angiogenesis, cell proliferation/survival and glucose metabolism but also in p53, p21 and signal transduction pathway in prostate cancer. Further studies of HIF-1 may yield new approaches to the diagnosis and treatment of prostate cancer. We present a review of the structure and biological functions of HIF-1 and its relation with prostate cancer.
Humans ; Hypoxia-Inducible Factor 1 ; physiology ; Male ; Prostatic Neoplasms ; diagnosis ; metabolism ; therapy

OBJECTIVETo investigate the value of detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer (PCa).

METHODSThe expressions of AMACR, P63 and 34betaE12 were examined in the biopsy specimens of 42 cases of prostate cancer, 12 cases of high-grade prostatic intraepithelial neoplasia (HGPIN) and 30 cases of benign prostatic hyperplasia (BPH) using the Maxvision single-step immunohistochemical method with triple-antibody cocktail (AMACR/P63/34betaE12) staining and double-color chromogens in single paraffin sections .

RESULTSThe expressions of AMACR, P63 and 34betaE12 were significantly different between PCa and BPH (P < 0.01). The staining of PCa was positive for AMACR and negative for P63 and 34betaE12, and the positivity rate of AMACR was 100%. BPH was strongly expressed for P63 and 34betaE12, but negatively for AMACR. The expression of AMACR was significantly different between HGPIN and BPH (P < 0.01), but not between HGPIN and PCa (P > 0.05), and the positivity rate of AMACR in HGPIN was 91.67%. However, the expressions of P63 and 34betaE12 were significantly different between HGPIN and PCa (P < 0.01), but not between HGPIN and BPH (P > 0.05), and the positivity rate of AMACR in HGPIN was 100%. The level of AMACR expression was not correlated with PCa Gleason score (P > 0.05).

CONCLUSIONAMACR is a sensitive and specific marker for PCa. P63 and 34betaE12 cocktail staining can increase the sensitivity and specificity of the basal cell detection. The immunohistochemical analysis with triple-antibody cocktail (AMACR/P63/34betaE12) staining and double-color chromogens can improve diagnostic accuracy and has an important applied value for the early diagnosis of prostate cancer.

Aged ; Carcinoma, Basal Cell ; diagnosis ; metabolism ; Early Diagnosis ; Humans ; Immunohistochemistry ; Keratins ; biosynthesis ; Male ; Membrane Proteins ; biosynthesis ; Middle Aged ; Prostatic Hyperplasia ; diagnosis ; metabolism ; Prostatic Neoplasms ; diagnosis ; metabolism ; Racemases and Epimerases ; biosynthesis

Adenoma ; metabolism ; pathology ; Biomarkers ; metabolism ; Biomarkers, Tumor ; metabolism ; Carcinoma, Basal Cell ; metabolism ; pathology ; Diagnosis, Differential ; Humans ; Hyperplasia ; Immunohistochemistry ; Male ; Prostate ; metabolism ; pathology ; Prostatic Hyperplasia ; metabolism ; pathology ; Prostatic Neoplasms ; metabolism ; pathology